Terminal › Stocks › NVAX

Novavax, Inc. (NVAX) Stock

Healthcare · Biotechnology · US

$9.13 -3.89%

Last updated Jun 19, 2026 00:03 UTC

NVAX Key Statistics

Market Cap$1.50B

P/E (TTM)-15.22

P/S (TTM)2.52

P/B (TTM)-10.30

Revenue (TTM)$596.34M

EPS (TTM)$-0.60

Dividend Yield—

ROE (TTM)89.73%

Net Margin-14.73%

Gross Margin84.64%

52W High$11.97

52W Low$6.13

Analyst ViewBuy

Price Target$18.00

Employees952

Volume7,506,997

About Novavax, Inc.

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

CEO: John Charles Jacobs. Company website

See NVAX live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open NVAX in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.